Wells Fargo & Company Xilio Therapeutics, Inc. Transaction History
Wells Fargo & Company
- $410 Billion
- Q1 2024
A detailed history of Wells Fargo & Company transactions in Xilio Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 108 shares of XLO stock, worth $102. This represents 0.0% of its overall portfolio holdings.
Number of Shares
108
Previous 106
1.89%
Holding current value
$102
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding XLO
# of Institutions
32Shares Held
10MCall Options Held
0Put Options Held
0-
Bain Capital Life Sciences Investors, LLC Boston, MA2.81MShares$2.67 Million0.46% of portfolio
-
River Vest Venture Management LLC St. Louis, MO1.44MShares$1.37 Million19.12% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD1.44MShares$1.37 Million0.04% of portfolio
-
Atlas Venture Life Science Advisors, LLC993KShares$943,2660.13% of portfolio
-
Vanguard Group Inc Valley Forge, PA903KShares$857,4040.0% of portfolio
About Xilio Therapeutics, Inc.
- Ticker XLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 27,471,600
- Market Cap $26.1M
- Description
- Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine prog...